8-K: CERO Secures $750K Convertible Note, Appoints New Director

CERO Therapeutics Holdings, Inc. announced a new $750,000 convertible note financing, a change in its independent auditor, and the appointment of Eric Francois to its board of directors.

Summary

• CERO Therapeutics Holdings, Inc. issued a convertible promissory note for a purchase price of $750,000, with a principal face value of $937,500, to Keystone Capital Partners, LLC.
• The note bears interest at 10% per annum and matures on July 9, 2027, allowing for borrowings up to a maximum aggregate amount of $1,000,000.
• The conversion price for common stock is the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices over 20 days, subject to a 4.99% beneficial ownership limitation.
• A unique clause mandates a cash payment to the lender if the calculated conversion price falls below the $0.05 floor price, effectively compensating the lender for the difference in share value.
• The company dismissed Wolf & Company, P.C. as its independent auditor, effective February 13, 2026, and appointed Salberg & Company, P.A., effective the same date.
• Wolf & Company's audit report for December 31, 2024, included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• Management also identified a material weakness in internal control over financial reporting due to a lack of sufficient and qualified resources.
• The Board of Directors increased its size from six to seven members and appointed Eric Francois as a new director, effective February 13, 2026.
• Mr. Francois brings extensive financial and capital markets experience from roles at Raymond James, Credit Suisse, Lazard Ltd, and as CFO of Scynexis, Inc.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with significant caution due to the 'going concern' warning, material weakness in internal controls, and the highly unfavorable terms of the convertible note, which heavily favor the lender and could lead to substantial dilution or cash outflows for the company.

Positives

• Secured $750,000 in financing (with a principal face value of $937,500) through a convertible promissory note, providing immediate capital.
• The note allows for potential additional borrowings up to $1,000,000, offering flexibility for future capital needs.
• Appointment of Eric Francois to the Board of Directors adds significant financial and capital markets expertise, potentially strengthening governance and strategic guidance.

Negatives

• The convertible note carries a high 10% annual interest rate.
• The conversion terms are highly favorable to the lender, including a cash payment mechanism if the stock price drops below the $0.05 floor price, which could be costly for the company and highly dilutive.
• The company must pay a 120% premium on the principal face value if it chooses to prepay the note, making early repayment expensive.
• The previous auditor, Wolf & Company, P.C., included an explanatory paragraph in its December 31, 2024, audit report regarding "substantial doubt about the Company's ability to continue as a going concern."
• Management identified a material weakness in internal control over financial reporting due to a lack of sufficient and qualified resources.
• The company faces penalties (additional 10% discount on conversion price and $1,500 fee per conversion) if its stock becomes "chilled" or receives a "Stop Sign" at DTC.

Risks

• Going Concern Risk: The previous auditor's report for December 31, 2024, highlighted "substantial doubt about the Company's ability to continue as a going concern."
• Financial Obligation and Dilution Risk: The convertible note creates a direct financial obligation with a 10% interest rate and significant potential for dilution if converted into common stock, especially given the favorable conversion terms for the lender.
• Cash Payment Risk on Conversion: The note includes a clause requiring a cash payment to the lender if the calculated conversion price falls below the $0.05 floor price, which could strain the company's liquidity.
• High Prepayment Penalty: Prepaying the note requires a 120% premium on the principal face value, making early debt reduction costly.
• Internal Control Weakness: A material weakness in internal control over financial reporting due to a lack of sufficient and qualified resources could lead to financial misstatements or operational inefficiencies.
• Regulatory and Trading Restrictions Risk: If the company's stock is "chilled" for deposit at DTC or receives a "Stop Sign," it incurs additional costs and a higher discount on conversion, indicating potential issues with market liquidity or regulatory compliance.
• Registration Statement Risk: Failure to file the required S-1 or S-3 registration statement by May 1, 2026, for the resale of conversion shares could lead to an event of default.

Future Outlook

The company is obligated to prepare and file a registration statement on Form S-1 or S-3 by May 1, 2026, to cover the resale of shares issuable upon conversion of the note. Eric Francois is expected to stand for election at the 2026 Annual Meeting of Stockholders.

Management Comments

• Management identified the existence of a material weakness in internal control over financial reporting related to the Company's conclusion that due to a lack of sufficient and qualified resources.

Industry Context

StockSavvy.ai notes that securing convertible debt financing is a common strategy for early-stage or growth companies, particularly in the therapeutics sector, to raise capital without immediate equity dilution at potentially unfavorable valuations. However, the terms of this note, especially the high interest rate, the cash payment clause for conversions below the floor price, and the significant prepayment penalty, suggest a challenging financing environment or a company with limited alternatives. The change in auditors, coupled with the previous auditor's going concern warning and identified material weakness in internal controls, raises red flags regarding financial stability and operational robustness, which are critical for investor confidence in the biotechnology and therapeutics industry. The appointment of a director with strong capital markets experience could be a move to address these financial challenges and improve investor relations.

Comparison to Industry Standards

• The 10% interest rate on the convertible note is on the higher side for corporate debt, even for smaller or riskier companies, suggesting a higher cost of capital compared to more established biotech firms. For example, larger pharmaceutical companies often secure debt at rates below 5%, while even venture debt for early-stage biotechs typically ranges from 8-12%, but often with less punitive conversion or prepayment terms.
• The conversion mechanism, which includes a cash payment to the lender if the stock price falls below the $0.05 floor price, is an aggressive anti-dilution and downside protection feature for the lender. This is not a standard feature in typical convertible notes and is highly favorable to the lender, indicating the company's weaker bargaining position.
• The 120% prepayment premium is also significantly higher than typical prepayment penalties, which often range from 100-105% of the principal, further highlighting the cost of this financing.
• The "going concern" explanatory paragraph from the previous auditor is a serious red flag, often seen in companies facing significant financial distress, unlike well-capitalized industry peers such as Amgen or Regeneron, which consistently demonstrate strong financial health.
• The identified material weakness in internal controls is a concern, as robust internal controls are a standard expectation for publicly traded companies, especially when compared to industry leaders who invest heavily in financial reporting infrastructure to ensure accuracy and compliance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution from the convertible note, especially given the lender-favorable conversion terms. The "going concern" warning and internal control weakness could negatively impact share price and investor confidence. The new director may bring valuable expertise.
• Creditors: The convertible note provides a new creditor (Keystone Capital Partners, LLC) with strong protections, including a high interest rate, cash payment on conversion, and a substantial prepayment premium, which could impact the company's ability to service other debts.
• Employees: The "going concern" warning and material weakness in internal controls could create uncertainty regarding job security and the company's long-term stability.
• Management: Faces the challenge of addressing the "going concern" issue, rectifying the material weakness in internal controls, and managing the terms of the new convertible debt.

Next Steps

• Company to prepare and file a registration statement on Form S-1 or S-3 by May 1, 2026, covering the resale of shares issuable upon conversion of the note.
• Eric Francois is expected to stand for election by the company's stockholders at the 2026 Annual Meeting.
• The NCG Committee and Board will confirm Eric Francois's independence for his potential role on the Audit Committee.
• The company will enter into an indemnification agreement with Eric Francois.

Key Dates

Recommendation

The filing reveals several critical negative factors: a "going concern" warning from the previous auditor, a material weakness in internal controls, and a highly unfavorable convertible note financing. The note's terms, including a 10% interest rate, a 120% prepayment premium, and a unique cash payment clause that protects the lender if the stock price falls below the conversion floor, indicate severe financial distress and a weak bargaining position for the company. These factors collectively point to significant financial instability, high dilution risk, and potential future cash flow issues, making the stock a high-risk investment with substantial downside potential.

Keywords

CERO Therapeutics, convertible note, financing, SEC filing, 8-K, corporate governance, auditor change, board appointment, financial risk, dilution, going concern, internal controls, Keystone Capital Partners, Eric Francois